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Abstract
Background: Extended-infusion cefepime (EIC) has been associated with decreased mortality in adults,
but to our knowledge, there are no studies in children. Objective: The objective of this study was to
determine the feasibility of implementing EIC as the standard dosing strategy in a pediatric population.
Methods: This was a descriptive study of children aged 1 month to 17 years, including patients in the
intensive care unit, who received cefepime after admission to a freestanding, tertiary care children’s
hospital. Patients were excluded if they were admitted to the neonatal intensive care unit or received
cefepime in the outpatient, operating, or emergency department areas. Demographic and clinical data for
patients who received cefepime from April through August 2013, the period following EIC
implementation, were extracted from the medical records. Results: A total of 150 patients were included
in the study, with a median age (interquartile range [IQR]) of 6 years (2-12.3 years) and median weight
(IQR) of 20.7 kg (13.2-42.8 kg); 143 patients received cefepime via extended infusions, and 10 (7.0%) of
those were changed to a 30-minute infusion during treatment. The most common reasons for infusion
time change were intravenous (IV) incompatibility and IV access concerns, responsible for 50% of
changes. Dosing errors and reported incidents during therapy were sparse (n = 12, 8.0%) and were most
commonly related to renal dosing errors and/or initial dose error by prescriber. Conclusions: Because
93.0% of the patients who initially received EIC remained on EIC, implementation of EIC as the standard
dosing strategy was feasible in this pediatric hospital.

Introduction
Infections caused by multidrug-resistant bacteria are increasing in prevalence in adults and
children and are associated with poor clinical outcomes.1-7 Less commonly used antibiotic
classes can be utilized in the treatment of multidrug-resistant bacteria, but many alternatives are
less than ideal. Carbapenems should be reserved for the treatment of serious Gram-negative
infections resistant to other β-lactams because increasing use may expedite the development of
resistance.8 Fluoroquinolones are conveniently and easily administered antibiotics; however, use
quickly promotes the development of resistant bacteria.8 Tigecycline has been suggested as a
treatment option, but its place in therapy is uncertain, particularly with limited experience in
children and a boxed warning for increase in mortality.9 Polymyxins, an older drug class
associated with nephrotoxicity concerns, are now being used again as a last resort.8 Polymyxin
dosing information in adults and children is limited, further complicating the treatment of serious
Gram-negative multidrug-resistant infections.
Though some new antimicrobials are in development, results from studies in pediatric
populations will be expected many years after studies in adults. With limited new antimicrobials
targeting resistant organisms available for pediatric use, practitioners must focus on optimizing
currently available agents to adequately treat children and improve overall outcomes.10 Broad
spectrum β-lactam antibiotics such as piperacillin/tazobactam and cefepime are commonly used
for empirical treatment of infections in hospitalized children. Optimization of cefepime dosing
regimens based on pharmacokinetic (PK) and pharmacodynamic (PD) parameters is one option
in expanding current use of the medication and limiting further development of antimicrobial
resistance.
Extrapolation of data regarding cefepime from adults to children is not simple. The elimination
half-life of cefepime is shorter in children aged 2 months to 16 years: 1.3 to 1.9 hours, as
compared with 2 to 2.3 hours observed in adults.11 A larger volume of distribution of cefepime—
0.37 L/kg as compared with 0.21 L/kg in adults—is also observed in the pediatric population.11
Bacterial killing by cefepime is dependent on the length of time that free drug concentrations
exceed the minimum inhibitory concentration (MIC; fT>MIC) for the bacterial pathogen.12,13
Given the more rapid elimination of cefepime in children, strategies to optimize fT>MIC in
children are critically important.
Courter et al14 utilized PK parameters obtained from healthy children and Monte Carlo
simulations to demonstrate that commonly recommended pediatric cefepime doses do not
achieve adequate PD exposures.14,15 Cefepime intravenous (IV) doses of 50 mg/kg/dose over 30
minutes every 12 and 8 hours achieved probabilities of target attainment of only 15% and 79%,
respectively, for Pseudomonas aeruginosa isolates, with MICs of 8 mg/L.14 However, when
cefepime was administered over 3 hours, probabilities of target attainment increased to 57% and
100% with every 12- and every 8-hour dosing, for the same P aeruginosa isolates.14 Despite the
potential to optimize the PD of cefepime in children as well as data suggesting tolerability,
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efficacy, and improved clinical outcomes in adults, extended-infusion cefepime (EIC) has not
been studied in hospitalized children.16,17 One reason may be concern that extended-infusion βlactam dosing is not feasible in children; however, Nichols et al4 demonstrated the feasibility of
extended-infusion piperacillin/tazobactam (EIPT) in a pediatric population with 92% of patients
continuing on an EIPT regimen. The objective of this study was to determine the feasibility of
implementing EIC as the standard dosing strategy in a pediatric population.
Methods
This was a prospective, descriptive study of hospitalized patients receiving cefepime following
implementation of the extended-infusion dosing strategy as standard of care at a tertiary care
children’s hospital. Patients aged 1 month through 17 years who received at least 1 dose of
cefepime from April through August 2013 were eligible for inclusion. Patients were excluded if
they were admitted to the neonatal intensive care unit (ICU) or received cefepime in the
outpatient, operating, or emergency department areas.
Following approval by the institution’s Pharmacy and Therapeutics Committee in April 2013,
the standard cefepime dose was changed from 50 mg/kg/dose IV every 8 hours, infused over 30
minutes, to the same dose and frequency infused over 4 hours. Doses were capped at 1 g for most
indications or 2 g for patients who weighed more than 100 kg or were being treated for central
nervous system (CNS) infections. During the study period, cefepime was ordered electronically
by prescribers using a specific electronic order form with prepopulated infusion times that also
provided decision support for indication and usual adult doses. Although the order set defaulted
the infusion time to 4 hours, prescribers were able to manually change the infusion duration to 30
minutes if desired.
Following cefepime initiation, researchers prospectively extracted patient demographic,
cefepime indication, and dosing information and cefepime-related outcome data from the
patients’ electronic medical records. Infections were defined as resolved based on treating
physician assessment and documentation and if antibiotic therapy was discontinued at discharge
from the hospital or at a follow-up visit with a health care provider. If patients did not have
positive cultures and cefepime was discontinued after empirical use, this was defined as “no
infection.” Febrile neutropenic patients were not included in this category. Death was designated
as the outcome if the patient died prior to discharge and the death was possibly caused by the
indication for cefepime. If cefepime was discontinued because of decline in clinical condition or
persistently positive cultures, the outcome was categorized as unsuccessful. Unknown outcome
was selected if there was insufficient documentation to determine the final outcome. Concurrent
medications and IV access points on the patient were documented at cefepime initiation and at
the time of a dosing change, if applicable. Therapy was defined as targeted if a specific infection
was treated (ie, cystic fibrosis exacerbation, positive culture) or empirical if cefepime was
administered for febrile neutropenia, for an infection of unknown etiology, or for a “rule-out”
course.
3

Data Analysis

The primary outcome of this study was the feasibility of EIC as determined by the percentage of
courses completing the 4-hour infusion instead of changing to the 30-minute infusion.
Coadministration feasibility, in the circumstances where cefepime and concurrent IV
medications were used, was determined if 2 or more doses of cefepime and the other medications
were successfully administered together. Secondary outcomes were infection resolution and
safety profile as documented in the medical record. Descriptive statistics were used for patient
demographics, percentage of cefepime courses administered via extended infusion, and
secondary outcomes. Analyses were conducted using Statistical Package for Social Sciences
version 19.0 (SPSS, Inc, Chicago, IL). The study was approved by the Indiana University
institutional review board.
Results
In all, 150 children with a median (interquartile range [IQR]) age of 6 years (2-12.3 years) and
weight 20.7 kg (13.2-42.8 kg) were included in the final analysis. The most common cefepime
indications were febrile neutropenia with or without bacteremia, sepsis or rule-out sepsis, urinary
tract infection/pyelonephritis, and cystic fibrosis (CF; Table 1). The hematology/oncology, stem
cell transplant, and pediatric critical care services were responsible for prescribing 54.6% of
cefepime courses. There were 75 positive cultures among 64 patients (42.7%). Positive cultures
were most commonly obtained from the blood, lungs, and urine: 30.7%, 18.7%, and 18.7%,
respectively. Gram-negative organisms were reported more frequently than Gram-positive
organisms in these body sites (39/52). Some patients had concomitant Gram-negative and Grampositive infections (9/52). The geometric mean MIC of isolated Gram-positive and Gramnegative organisms for cefepime, when MIC data were available, was 1.3. A cefepime-specific
MIC was not documented for each Gram-positive isolate in accordance with laboratory practices,
so nonsusceptibility was inferred from oxacillin and ceftriaxone MICs in some cases. 18 Of 39
Gram-negative isolates with documented cefepime MIC values, including 17 Pseudomonas
isolates, MIC values for 24 isolates (61.5%) were 1 mg/L, 8 (20.5%) values were 2 mg/L, 1
value (2.6%) was 4 mg/L, 4 (10.3%) were 8 mg/L, and 2 (5.1%) were 16 mg/L. For some
mucoid P aeruginosa isolates, the lab performed Kirby Bauer tests for susceptibility, so MIC
values were not known. Microbiological culture data are shown in Table 2. The mean (SD)
estimated glomerular filtration rate as assessed via the modified equation suggested by Schwartz
et al19 (mL/min/1.73 m2) at cefepime initiation was 129 (5). Of the patients treated during the
study, 32 (21.3%) were hospitalized in an ICU. The median (IQR) length of stay in the ICU was
3 days (2-6.8 days). Patients receiving EIC were treated for a median duration of 6 days (IQR =
3-10 days; range = 1-35 days) and experienced a median hospital stay of 14 days (IQR = 7-31
days; range = 2-160 days). Patients who received the 30-minute infusion were also treated for a
median duration of 6 days (IQR = 3-13 days; range = 2-15 days) and were in the hospital for a
total of 13 days (IQR = 4-55 days; range = 2-55 days).
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EIC was initiated in 95.3% (143/150) of patients, whereas 4.7% (7/150) initially received the 30minute infusion. Most patients received every-8-hour dosing, but 10 patients received different
intervals because of adjustment for impaired renal function. In all, 133 patients (93.0%)
remained on EIC throughout the duration of the cefepime course. Also, 11 patients had the
infusion time changed from 4 hours to 30 minutes, and 2 patients had the infusion time changed
from 30 minutes to 4 hours. In these cases, the median (IQR) day of change was the fourth day
(second to tenth), and the infusion time was changed as a result of IV access issues in 50% (n =
6) of cases. Specific reasons for changing from EIC to a 30-minute infusion were
incompatibility/not enough access (n = 2, 18.2%), preventive change by prescriber as a result of
potential future access concerns (n = 2, 18.2%), prescriber preference (n = 2, 18.2%), patient
freedom (n = 1, 9.1%), planning for discharge (n = 1, 9.1%), and nurse concern that precipitates
were forming when multiple medications were coadministered (n = 1, 9.1%). The remaining 2
reasons for changing from EIC to a 30-minute infusion were not documented.
At cefepime initiation, 30% of patients had only peripheral access, 52% had only central IV
access, and 18% of patients had both central and peripheral access. Patient IV access and
concurrent IV medications are displayed in Table 3. Among all patients receiving additional IV
medications, the most common concomitant therapies were antimicrobials, analgesics or
sedatives, and antiemetics in 53.3%, 30.7%, and 22.7% of patients, respectively. The most
commonly administered concurrent antimicrobials during cefepime treatment were vancomycin
(n = 57/150, 38%), aminoglycosides (n = 13/150, 8.7%), and metronidazole (n = 9/150, 6%).
Concurrent antimicrobials were not necessarily coadministered in all patient cases.
Coadministration in which the antimicrobials were infused at the same time as the cefepime
occurred with vancomycin (n = 37/57, 64.9%), aminoglycosides (n = 6/13, 46.2%), and
metronidazole (n = 8/9, 88.9%). Though there were 136 patients who received at least one
additional IV medication while receiving cefepime, there were no documented complications
caused by IV access or incompatibility with the concurrent IV medications.
At the completion of cefepime therapy, 36.7% (55/150) of patients were determined to have had
no infection. Of those who had documented or suspected infection, the infectious indication was
considered to be resolved in 86.3% (82/95) of patients. Of the remaining 13 patients, 6 patients
died, 4 had an unknown outcome because of lack of follow-up information from the primary care
physician, and 3 patients required an antimicrobial change based on a decline in clinical
condition requiring empirical escalation. Of the 6 deaths, only 2 were possibly caused by
infection. One complicated patient with cystic fibrosis exacerbation and sepsis ultimately died.
At the time of death, the patient had a positive respiratory sputum culture, including 3 different
multidrug-resistant P aeruginosa isolates (2 resistant to cefepime and all other antibiotics except
colistin and tobramycin and 1 isolate with a cefepime MIC of 16 mg/L) and methicillin-resistant
Staphylococcus aureus. The other patient was undergoing therapy for relapsed acute myeloid
leukemia (AML) prior to development of infection for which the patient initially received
cefepime. Unfortunately, prior to completion of therapy the patient’s clinical condition declined
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and palliative care was initiated. The other 4 deceased patients all died because of a preexisting
medical condition, including 2 cases of stage IV neuroblastoma, severe anemia attributed to
hemophagocytic lymphohistiocytosis, and multivisceral organ transplant rejection. The 3 patients
requiring an antimicrobial change based on a decrease in clinical condition were all being
empirically treated for febrile neutropenia. One of the 3 patients developed Clostridium difficile
infection while receiving cefepime. The other 2 patients had negative cultures; one developed
typhlitis and liver abscesses of unknown pathology while receiving cefepime, and the other was
treated at an outside hospital for typhlitis several days after discharge and cefepime completion.
Cefepime was commonly used for the management of febrile neutropenia. Positive cultures were
present in 28.8% (17/59) of febrile neutropenic patients, most commonly in the blood (13/17).
The most common microorganisms in febrile neutropenic patients with a positive culture were P
aeruginosa (4/17) and Enterobacter cloacae (3/17). EIC was completed without infusion time
change in 96.6% (57/59) of febrile neutropenic patients. Febrile neutropenic patients received
cefepime for a median (IQR) of 9 days (5-15 days) and were hospitalized for a median (IQR) of
27 days (10-33 days).
A total of 12 cefepime dosing errors occurred in 12 (8%) patients. All 12 patients received EIC.
Table 4 describes the errors and the suspected root causes. No error-related adverse effects were
documented.
Discussion
Infections caused by resistant bacteria or bacteria with reduced susceptibility are increasing in
prevalence, making it critical to obtain and maintain adequate antibiotic exposures against the
pathogenic microorganism.1⇓-3 PK studies in adults have demonstrated that extended cefepime
infusions result in optimized fT>MIC for bacteria with elevated MICs, as have mathematical
simulations in both children and adults.17,20⇓-22 Bauer et al17 report findings suggesting that EIC
reduced mortality rates in adult patients with P aeruginosa infections. Overall mortality in
patients was significantly lower in patients treated with EIC as compared with a 30-minute
infusion time (20% vs 3%).17 The median length of hospital stay was similar for patients
receiving EIC, but for patients admitted in the ICU, the median length of stay was 10.5 days
shorter for patients receiving EIC.17 In addition to improved patient outcomes, optimizing PD
properties of β-lactams may delay development of future resistance, though this has proved to be
difficult to evaluate. To our knowledge, following PubMed and EMBASE literature database
searches, this is the first study evaluating EIC in children. In our cohort, EIC was successfully
implemented as the standard dosing strategy and was used in 96% of patients. Less than 10% of
patients who were initially started on EIC were changed to a 30-minute infusion time, and just
over half of those were because of IV access concerns. The comparison of outcomes in these
patients with patients receiving a 30-minue infusion of cefepime was beyond the scope of the
current study but is a consideration for future research.
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These findings are similar to those from a 2012 EIPT study, which reported that EIPT can be
successfully adopted as standard care in a pediatric hospital.4 In all, 92% of patients involved in
the study were able to receive EIPT, which is similar to the results for EIC. Of the 8% in the
previous study who did not receive EIPT and instead received a 30-minute infusion, the most
common reason was incompatibility with coprescribed vancomycin.4,23 In the present study,
changes from EIC to a 30-minute infusion were primarily a result of IV access concerns.
Although these concerns were the reason for change in more than half of the patients, this does
represent a small number of total patients (n = 6). Though IV access in children, particularly
younger infants, may be difficult to obtain and maintain, the IV access concerns in our cohort are
interesting, given that the distribution of IV and peripheral access points and receipt of
concurrent IV medications in the patients who received 30-minute infusions were similar to
those in patients who received 4-hour infusions. A nursing and provider education campaign
focusing on IV access maintenance and cefepime compatibility may be a strategy to maintain
100% use of EIC, but we would not recommend adding additional access for the sole purpose of
EIC.
We believe that one key to the success in implementing EIC as a standard dosing strategy in
pediatric patients was staff education. Traditional infusion times of 30 minutes have been used in
pediatric institutions for many years, and implementing change is challenging. At our freestanding hospital within a larger health care system, implementation of standard EIC followed
the same steps as our previous transition to EIPT. The institution’s Pharmacy and Therapeutics
Committee approved the infusion time change as an automatic interchange at both adult and
children’s hospitals within the system. Pharmacists were provided a pharmacy-specific
educational handout and verbal education with a chance to ask questions during daily pharmacy
collaboration meetings. Nurse educators dispersed a nursing-specific educational handout along
with verbal education to the nursing staff through usual nursing education routes. Chief medical
residents distributed main points of EIC education to the remainder of the medical residents.
Required electronic order forms were utilized for cefepime ordering by prescribers with a 4-hour
infusion time default. The order forms provided decision support regarding doses in child- and
adult-sized patients and a place to document a desire and rationale for shorter infusion times.
Continued vigilance and education can be utilized to minimize future errors and prevent
prescribers from switching infusion times during treatment because of IV access and
incompatibility concerns when there are none. In all, 8 errors that occurred were linked to
prescribing, which could have been potentially prevented through education about EIC.
Prescribers who erroneously altered treatment infusion times can be reeducated to prevent
unneeded changes in future patients. The remaining 4 errors that occurred were more likely a
result of other root causes and not a change to EIC.
Positive clinical outcomes without major complications were observed in patients receiving EIC,
but comparison of outcomes with patients receiving traditional 30-minute infusions were beyond
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the scope of this study. Further studies examining the outcomes of 30-minute infusion and EIC in
pediatrics should be performed to allow conclusions regarding safety and efficacy of EIC.
Current lack of comparative outcomes data in children may hinder the adoption of EIC in other
pediatric institutions, particularly because this dosing strategy requires increased IV access use
and increases the potential for IV compatibility issues with other medications. Anecdotally, the
increased time that a patient is attached to an IV pole has not been a problem in our institution,
and compatibility issues can be addressed with a change in infusion duration. From a cost
perspective, because the dose (50 mg/kg) does not change in smaller patients, no difference in
cost is expected. In appropriate patients who weigh >20 kg, without CNS infections, a cost
benefit can be realized by capping the dose at 1000 mg IV every 8 hours instead of continuing
weight-based dosing up to a maximum of 2000 mg.21 Specific cost comparison was beyond the
scope of the current study.
One strategy might be to use EIC only in critically ill patient populations or in patients infected
with organisms with demonstrated elevated MICs. However, elevated MICs and resistance to βlactams such as piperacillin/tazobactam and cefepime are becoming more common in
hospitalized patients.24 Of the 39 Gram-negative isolates with documented cefepime MIC values
in our study, 18% (7 isolates) displayed an elevated MIC of 4 µg/mL or greater. In the study by
Bauer et al,17 >30% of the P aeruginosa isolates exhibited an MIC to cefepime of ≥8 mg/L.17
Though specific MIC distributions were not provided, in the study by Courter et al, 14 the MIC90
for P aeruginosa isolates in 2 pediatric specialty hospitals was 16 mg/L for cefepime and
piperacillin/tazobactam. Because cefepime is frequently initiated prior to isolation and
susceptibility testing of an organism, when appropriate antibiotic choice is most important, use
of an optimized dosing strategy in all patients lessens the chance of “missing” a resistant
organism. Additionally, consistent use of EIC is likely to reduce confusion and drug errors as
nurses become accustomed to always infusing doses over 4 hours. Additionally, although EIC
may not confer a clear outcomes benefit over traditional infusion in all patients, particularly
those infected with organisms with lower MICs, it is unlikely to increase the risk of harm.
Conclusion
Implementation of EIC as the standard dosing strategy was feasible at this children’s hospital,
with 93% of patients (except those admitted to the neonatal ICU or those receiving cefepime in
the outpatient, operating, or emergency department areas per exclusion criteria) continuing to
receive EIC. In efforts to optimize antimicrobial dosing and use, other children’s hospitals are
encouraged to utilize these findings within their institutions. Further studies evaluating the
clinical outcomes of EIC would aid in the widespread adoption of this dosing practice.
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